ERG expression levels in prostate tumors reflect functional status of the androgen receptor (AR) as a consequence of fusion of ERG with AR regulated gene promoters

Open Cancer Journal

Volumn 3, Issue SPEC. ISSUE 1, 2010, Pages 101-108

  Dobi, Albert ^a   Furusato, Bungo ^a,b   Shaheduzzaman, Syed ^a   Chen, Yongmei ^a   Vahey, Maryanne ^d   Nydam, Timothy ^a,c   Sesterhenn, Isabell A ^a,b   McLeod, David G ^a,c   Petrovics, Gyorgy ^a   Srivastava, Shiv ^a  

^a UNIFORMED SERVICES UNIVERSITY OF THE HEALTH SCIENCES   (United States)

^b ARMED FORCES INSTITUTE OF PATHOLOGY   (United States)

^c WALTER REED ARMY MEDICAL CENTER   (United States)

^d WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

Androgen receptor; ERG; Oncogene; Prostate cancer; TMPRSS2 ERG

Indexed keywords

ANDROGEN RECEPTOR;

ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION; GENE FUSION; HUMAN; HUMAN CELL; HUMAN TISSUE; MALE; NUCLEOTIDE SEQUENCE; ONCOGENE ERG; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE TUMOR; PROTO ONCOGENE; SIGNAL TRANSDUCTION; TRANSCRIPTION REGULATION; TUMOR CELL;

EID: 78249235620     PISSN: None     EISSN: 18740790     Source Type: Journal    
DOI: 10.2174/1874079001003010101     Document Type: Article

References (56)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
2. Tomlins SA, Rhodes DR, Perner S, et al. Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. Science 2005; 310: 644-648.
3. Helgeson BE, Tomlins SA, Shah N, et al. Characterization of TMPRSS2: ETV5 and SLC45A3: ETV5 gene fusions in prostate cancer. Cancer Res 2008; 68: 73-80.
4. Pflueger D, Rickman DS, Sboner A, et al. N-myc downstream regulated gene 1 (NDRG1) is fused to ERG in prostate cancer. Neoplasia 2009; 11: 804-811.
5. Turner DP, Watson DK. ETS transcription factors: oncogenes and tumor suppressor genes as therapeutic targets for prostate cancer. Expert Rev Anticancer Ther 2008; 8: 33-42.
6. Kumar-Sinha C, Tomlins SA, Chinnaiyan AM. Recurrent gene fusions in prostate cancer. Nat Rev Cancer 2008; 8: 497-511.
7. Clark JP, Cooper CS. ETS gene fusions in prostate cancer. Nat Rev Urol 2009; 6: 429-439.
8. Heinlein CA, Chang C. Androgen receptor in prostate cancer. Endocr Rev 2004; 25: 276-308.
9. Linja MJ, Visakorpi T. Alterations of androgen receptor in prostate cancer. J Steroid Biochem Mol Biol 2004; 92: 255-264.
10. Shaffer DR, Scher HI. Prostate cancer: a dynamic illness with shifting targets. Lancet Oncol 2003; 4: 407-414.
11. Chen CD, Welsbie DS, Tran C, et al. Molecular determinants of resistance to antiandrogen therapy. Nat Med 2004; 10: 33-39.
12. [12] Sarker D, Reid AH, Yap TA, de Bono JS. Targeting the PI3K/AKT pathway for the treatment of prostate cancer. Clin Cancer Res 2009; 15: 4799-4805.
13. Sun C, Shi Y, Xu LL, et al. Androgen receptor mutation (T877A) promotes prostate cancer cell growth and cell survival. Oncogene 2006; 25: 3905-3913.
14. Alimirah F, Panchanathan R, Chen J, et al. Expression of androgen receptor is negatively regulated by p53. Neoplasia 2007; 9: 1152-1159.
15. Rokhlin OW, Taghiyev AF, Guseva NV, et al. Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene 2005; 24: 6773-6784.
16. Dehm SM, Tindall DJ. Molecular regulation of androgen action in prostate cancer. J Cell Biochem 2006; 99: 333-344.
17. Nieto M, Finn S, Loda M, Hahn WC. Prostate cancer: Re-focusing on androgen receptor signaling. Int J Biochem Cell Biol 2007; 39: 1562-1568.
18. Richter E, Srivastava S, Dobi A. Androgen receptor and prostate cancer. Prostate Cancer Prostatic Dis 2007; 10: 114-118.
19. Montgomery RB, Mostaghel EA, Vessella R, et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 2008; 68: 4447-4454.
20. Petrovics G, Liu A, Shaheduzzaman S, et al. Frequent overexpression of ETS-related gene-1 (ERG1) in prostate cancer transcrip-tome. Oncogene 2005; 24: 3847-3852.
21. Hu Y, Dobi A, Sreenath T, et al. Delineation of TMPRSS2-ERG splice variants in prostate cancer. Clin Cancer Res 2008; 14: 4719-4725.
22. Segawa T, Nau ME, Xu LL, et al. Androgen-induced expression of endoplasmic reticulum (ER) stress response genes in prostate cancer cells. Oncogene 2002; 21: 8749-8758.
23. Xu LL, Su YP, Labiche R, et al. Quantitative expression profile of androgen-regulated genes in prostate cancer cells and identification of prostate-specific genes. Int J Cancer 2001; 92: 322-328.
24. Shaheduzzaman S, Vishwanath A, Furusato B, et al. Silencing of Lactotransferrin expression by methylation in prostate cancer progression. Cancer Biol Ther 2007; 6: 1088-1095.
25. Owczarek CM, Portbury KJ, Hardy MP, et al. Detailed mapping of the ERG-ETS2 interval of human chromosome 21 and comparison with the region of conserved synteny on mouse chromosome 16. Gene 2004; 324: 65-77.
26. Morrow PK, Hortobagyi GN. Management of breast cancer in the genome era. Annu Rev Med 2009; 60: 153-165.
27. Szabo J, Bartok K, Krenacs T, Szepesvary Z, Szende B. GnRH receptor and androgen receptor status and outcome of advanced prostate carcinomas. Anticancer Res 2009; 29: 681-684.
28. Romics I, Banfi G, Szekely E, Krenacs T, Szende B. Expression of p21(waf1/cip1), p27 (kip1), p63 and androgen receptor in low and high Gleason score prostate cancer. Pathol Oncol Res 2008; 14: 307-311.
29. Qiu YQ, Leuschner I, Braun PM. Androgen receptor expression in clinically localized prostate cancer: immunohistochemistry study and literature review. Asian J Androl 2008; 10: 855-863.
30. Donovan MJ, Osman I, Khan FM, et al. Androgen receptor expression is associated with prostate cancer-specific survival in castrate patients with metastatic disease. BJU Int 2010; 105(4): 462-467.
31. Wako K, Kawasaki T, Yamana K, et al. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 2008; 61: 448-454.
32. Xu LL, Shi Y, Petrovics G, et al. PMEPA1, an androgen-regulated NEDD4-binding protein, exhibits cell growth inhibitory function and decreased expression during prostate cancer progression. Cancer Res 2003; 63: 4299-4304.
33. Xu LL, Shanmugam N, Segawa T, et al. A novel androgen-regulated gene, PMEPA1, located on chromosome 20q13 exhibits high level expression in prostate. Genomics 2000; 66: 257-263.
34. Masuda K, Werner T, Maheshwari S, et al. Androgen receptor binding sites identified by a GREF_GATA model. J Mol Biol 2005; 353: 763-771.
35. Wang Q, Li W, Liu XS, et al. A hierarchical network of transcription factors governs androgen receptor-dependent prostate cancer growth. Mol Cell 2007; 27: 380-392.
36. Velasco AM, Gillis KA, Li Y, et al. Identification and validation of novel androgen-regulated genes in prostate cancer. Endocrinology 2004; 145: 3913-3924.
37. Wang Q, Li W, Zhang Y, et al. Androgen receptor regulates a distinct transcription program in androgen-independent prostate cancer. Cell 2009; 138: 245-256.
38. Heemers HV, Tindall DJ. Androgen receptor (AR) coregulators: a diversity of functions converging on and regulating the AR transcriptional complex. Endocr Rev 2007; 28: 778-808.
39. Sterbis JR, Gao C, Furusato B, et al. Higher expression of the androgen-regulated gene PSA/HK3 mRNA in prostate cancer tissues predicts biochemical recurrence-free survival. Clin Cancer Res 2008; 14: 758-763.
40. Mendiratta P, Mostaghel E, Guinney J, et al. Genomic strategy for targeting therapy in castration-resistant prostate cancer. J Clin Oncol 2009; 27: 2022-2029.
41. Tomlins SA, Mehra R, Rhodes DR, et al. Integrative molecular concept modeling of prostate cancer progression. Nat Genet 2007; 39: 41-51.
42. Hermans KG, van Marion R, van Dekken H, et al. TMPRSS2: ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. Cancer Res 2006; 66: 10658-10663.
43. Varambally S, Yu J, Laxman B, et al. Integrative genomic and proteomic analysis of prostate cancer reveals signatures of metastatic progression. Cancer Cell 2005; 8: 393-406.
44. Hendriksen PJ, Dits NF, Kokame K, et al. Evolution of the androgen receptor pathway during progression of prostate cancer. Cancer Res 2006; 66: 5012-5020.
45. Bismar TA, Demichelis F, Riva A, et al. Defining aggressive prostate cancer using a 12-gene model. Neoplasia 2006; 8: 59-68.
46. Magee JA, Abdulkadir SA, Milbrandt J. Haploinsufficiency at the Nkx3.1 locus. A paradigm for stochastic, dosage-sensitive gene regulation during tumor initiation. Cancer Cell 2003; 3: 273-283.
47. Shen MM, Wang X, Economides KD, Walker D, Abate-Shen C. Progenitor cells for the prostate epithelium: roles in development, regeneration, and cancer. Cold Spring Harb Symp Quant Biol 2008; 73: 529-538.
48. Sun C, Dobi A, Mohamed A, et al. TMPRSS2-ERG fusion, a common genomic alteration in prostate cancer activates C-MYC and abrogates prostate epithelial differentiation. Oncogene 2008; 27: 5348-5353.
49. Zong Y, Xin L, Goldstein AS, et al. ETS family transcription factors collaborate with alternative signaling pathways to induce carcinoma from adult murine prostate cells. Proc Natl Acad Sci USA 2009; 106: 12465-12470.
50. Klezovitch O, Risk M, Coleman I, et al. A causal role for ERG in neoplastic transformation of prostate epithelium. Proc Natl Acad Sci USA 2008; 105: 2105-2110.
51. Tomlins SA, Laxman B, Varambally S, et al. Role of the TMPRSS2-ERG gene fusion in prostate cancer. Neoplasia 2008; 10: 177-188.
52. Winnes M, Lissbrant E, Damber JE, Stenman G. Molecular genetic analyses of the TMPRSS2-ERG and TMPRSS2-ETV1 gene fusions in 50 cases of prostate cancer. Oncol Rep 2007; 17: 1033-1036.
53. Hermans KG, Boormans JL, Gasi D, et al. Overexpression of prostate-specific TMPRSS2(exon 0)-ERG fusion transcripts corresponds with favorable prognosis of prostate cancer. Clin Cancer Res 2009; 15: 6398-6403.
54. Saramaki OR, Harjula AE, Martikainen PM, et al. TMPRSS2: ERG fusion identifies a subgroup of prostate cancers with a favorable prognosis. Clin Cancer Res 2008; 14: 3395-3400.
55. Gopalan A, Leversha MA, Satagopan JM, et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. Cancer Res 2009; 69: 1400-1406.
56. Bonaccorsi L, Nesi G, Nuti F, et al. Persistence of Expression of the tmprss2: erg fusion gene after presurgery androgen ablation may be associated with early psa relapse of prostate cancer: preliminary results. J Endocrinol Invest 2009; 32: 590-596.